Purple Biotech (PPBT) Other Non-Current Assets (2018 - 2026)
Purple Biotech (PPBT) posted quarterly Other Non-Current Assets of $7.6 million for Q1 2026, down 72.8% year-over-year from $28.1 million in Q1 2025, and down 0.88% quarter-over-quarter from $7.7 million in Q4 2025.
Purple Biotech (PPBT) Other Non-Current Assets (2018 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Other Non-Current Assets for 9 consecutive years, with $7.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 72.8% year-over-year to $7.6 million; the TTM figure through Mar 2026 stood at $7.6 million (down 72.8% YoY), while the FY2025 annual figure was $7.7 million, up 128333.33% from the prior year.
- Other Non-Current Assets slipped to $7.6 million in Q1 2026 per PPBT's latest filing, from $7.7 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $28.7 million in Q1 2023 and bottomed at $6000.0 in Q4 2023.
- Historically, Other Non-Current Assets has averaged $18.3 million across 5 years, with a median of $26.2 million in 2022.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets slumped 93.75% — and 2025, when it jumped 128333.33%.
- Purple Biotech's Other Non-Current Assets stood at $10000.0 in 2022, then sank by 40.0% to $6000.0 in 2023, then changed by 0.0% to $6000.0 in 2024, then surged by 128333.33% to $7.7 million in 2025, then dropped by 0.88% to $7.6 million in 2026.
- Business Quant data shows PPBT's Other Non-Current Assets at $7.6 million in Q1 2026, $7.7 million in Q4 2025, and $28.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 62.96 Mn |
| 10 | Purple Biotech | 127.07 | 127.07 | - | 7.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.64 Mn |
| Dec 31, 2025 | 7.71 Mn |
| Jun 30, 2025 | 28.07 Mn |
| Mar 31, 2025 | 28.08 Mn |
| Dec 31, 2024 | 6,000.00 |
| Sep 30, 2024 | 28.17 Mn |
| Jun 30, 2024 | 28.20 Mn |
| Mar 31, 2024 | 28.46 Mn |
| Dec 31, 2023 | 6,000.00 |
| Sep 30, 2023 | 28.55 Mn |
| Jun 30, 2023 | 28.62 Mn |
| Mar 31, 2023 | 28.67 Mn |
| Dec 31, 2022 | 10,000.00 |
| Sep 30, 2022 | 24.24 Mn |
| Jun 30, 2022 | 24.29 Mn |
| Mar 31, 2022 | 2.66 Mn |
| Dec 31, 2021 | 160,000.00 |
| Sep 30, 2021 | 5.02 Mn |
| Jun 30, 2021 | 5.02 Mn |
| Mar 31, 2021 | 3.07 Mn |